Loading clinical trials...
Loading clinical trials...
A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK0364) in Obese Patients and in Overweight Patients With Obesity-Related Co-Morbidities, Followed by a 1-Year Extension
Conditions
Interventions
taranabant
placebo
Start Date
October 1, 2006
Primary Completion Date
January 1, 2008
Completion Date
December 1, 2008
Last Updated
March 13, 2015
NCT01143454
NCT07472881
NCT07010757
NCT06223555
NCT06989203
NCT07237750
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions